Jasper Therapeutics Inc

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for mast stem cell driven diseases in the United States. Its lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. The company develops and commercializes therapeutic agents for patients with mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Founded in 2018, Jasper Therapeutics is headquartered in Redwood City, California.